Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma
Conclusion: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Docetaxel | Sarcomas | Study | Synovial Sarcoma | Taxotere